Please select a Capability in order to start your service request.
First Healthcare Institution in the U.S. to Implement the SystemJun 17, 2014
FRANKLIN LAKES, N.J., June 17, 2014 – BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with The University of Texas MD Anderson Cancer Center for BD Cato™, a system that enhances safety and workflow efficiency in medication preparation via gravimetric and barcoding technology. MD Anderson Cancer Center will be the first healthcare institution in the U.S. to implement the BD Cato System and will be incorporating the system into its outpatient infusion pharmacies, including community-based locations.
“We are pleased to provide MD Anderson Cancer Center with the BD Cato system and the increased assurance that the right patient is receiving the right medication in the right dose,” said William A. Tozzi, President, BD Medical – Medical Surgical Systems. “Medication errors are one of the top concerns on the minds of healthcare providers today and the BD Cato system offers a significant step forward in improving safety and patient outcomes, while also optimizing workflow efficiencies.”
BD Cato Workflow Solution provides an automated system that creates and shares data to reduce the possibility of human error, standardize practice, streamline workflow and increase efficiency from medication preparation to delivery in the pharmacy. The software detects potential medication errors and associated costs, automates documentation, and optimizes drug utilization to reduce drug waste. The system interfaces with Pharmacy IT systems to pull in physician orders and allow dose queue management within the preparation environment, thereby simultaneously improving safety and efficiency.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.